Tony Kingsley

Tony Kingsley is a biopharmaceutical executive who runs Stablix, Inc., a New York biotech betting that you can treat disease by protecting proteins instead of destroying them. He took the CEO seat in February 2022 after a career of running one drug company after another - Scholar Rock, TARIS Bio, The Medicines Company - and heading global commercial at Biogen, with a McKinsey partnership and a stint in medical devices before that. In July 2025 he joined the board of Indivior. He holds a Dartmouth degree and a Harvard MBA.